Search Within

Michael Morris

Formats
  1. Meeting Abstract (273)
  2. Journal Article (266)
  3. Review (19)
  4. Book Section (6)
  5. Editorial (6)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Miscellaneous (2)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (580)
  2. Genitourinary Oncology Service (580)
  3. Solid Tumor Oncology Division (580)
  4. Radiology, Department of (163)
  5. GSK Faculty (161)
  6. Molecular Imaging and Therapy Service (140)

More Groups

People
  1. Howard Scher (217)
  2. Steven Larson (93)
  3. Susan Slovin (90)
  4. Dana Rathkopf (79)
  5. Daniel Danila (54)
  6. Glenn Heller (54)

More People

Years
  1. 2025 (21)
  2. 2024 (50)
  3. 2023 (40)
  4. 2022 (50)
  5. 2021 (42)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (238)
  2. Journal of Nuclear Medicine (43)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (30)
  5. Cancer (18)
  6. European Urology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (248)
  2. American Association for Cancer Research (43)
  3. Society of Nuclear Medicine (43)
  4. Oxford University Press (41)
  5. Elsevier Science, Inc. (39)
  6. Elsevier Inc. (27)

More Publishers

Results (580)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The Lancet Commission on prostate cancer: Planning for the surge in cases
    Review

    James, N. D.; Tannock, I.; N'Dow, J.; Feng, F.; Gillessen, S.; Ali, S. A.; Trujillo, B.; Al-Lazikani, B.; Attard, G.; Bray, F.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Radiographic progression-free survival and clinical progression-free survival as potential surrogates for overall survival in men with metastatic hormone-sensitive prostate cancer
    Journal Article

    Halabi, S.; Roy, A.; Rydzewska, L.; Guo, S.; Godolphin, P.; Hussain, M.; Tangen, C.; Thompson, I.; Xie, W.; Carducci, M. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)
    Journal Article

    Aggarwal, R.; Heller, G.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T.; Appleman, L.; Weckstein, D.; Patnaik, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Safety analyses of the phase 3 VISION trial of [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Journal Article

    Chi, K. N.; Armstrong, A. J.; Krause, B. J.; Herrmann, K.; Rahbar, K.; de Bono, J. S.; Adra, N.; Garje, R.; Michalski, J. M.; Kempel, M. M.; more...
    European Urology (2024)

    Fulltext@MSK | Save
  • Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)
    Journal Article

    Patel, J. N.; Jiang, C.; Owzar, K.; Hertz, D. L.; Wang, J.; Mulkey, F. A.; Kelly, W. K.; Halabi, S.; Furukawa, Y.; Lassiter, C.; more...
    Pharmacogenomics Journal (2024)

    Fulltext@MSK | Save
  • Costs to Medicare of nonrecommended bone-modifying agent use for castration-sensitive prostate cancer
    Journal Article

    Mitchell, A. P.; Nemirovsky, D.; Mishra Meza, A.; Chakraborty, N.; Persaud, S.; Farooki, A.; Morris, M. J.
    JCO Oncology Practice (2024)

    Fulltext@MSK | Save
  • Phase I study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer progressing on enzalutamide
    Journal Article

    Abida, W.; Hahn, A. W.; Shore, N.; Agarwal, N.; Sieber, P.; Smith, M. R.; Dorff, T.; Monk, P.; Rettig, M.; Patel, R.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Design considerations in the PSMAfore trial
    Editorial

    Sartor, O.; Fizazi, K.; Herrmann, K.; Morris, M. J.
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Telemedicine and cancer care: Barriers and strategies to optimize delivery
    Review

    Doshi, S. D.; Bange, E. M.; Daly, B.; Kuperman, G.; Panageas, K. S.; Morris, M. J.
    The Cancer Journal (2024)

    Fulltext@MSK | Save
  • Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial
    Journal Article

    Sumiyoshi, T.; Wang, X.; Warner, E. W.; Sboner, A.; Annala, M.; Sigouros, M.; Beja, K.; Mizuno, K.; Ku, S.; Fazli, L.; more...
    JNCI: Journal of the National Cancer Institute (2024)

    Fulltext@MSK | Save